Financial Comparison
Abbott Laboratories vs Johnson & Johnson
Click a ticker to view the full analysis.
In short
Johnson & Johnson is the more profitable of the two, keeping 28.5% of revenue as net profit against 14.7% for Abbott Laboratories. Johnson & Johnson trades at the higher trailing P/E (39.1× vs 31.9× for Abbott Laboratories), so investors pay more for each dollar of its earnings. Fisclear flags 1 medium- or high-severity risk for Abbott Laboratories and 1 for Johnson & Johnson.
Based on filings for periods ending 30 Jun 2026 (ABT) and 27 Sept 2026 (JNJ) · Updated
FisclearScore Comparison
FisclearScore is a quantitative model. ABT shown solid · JNJ shown dashed. Not financial advice.
| Metric | ABT | JNJ |
|---|---|---|
| Price | $98.49 | $257.78 |
| Market Cap | $171.6B | $621.2B |
| P/E (TTM) | 31.9x | 39.1x |
| P/B | 3.3x | 7.3x |
| Beta | 0.58 | 0.21 |
| Div Yield | 2.48% | 2.07% |
| Revenue (TTM) | $44.3B | $94.2B |
| Net Income | $6.5B | $26.8B |
| Gross Margin | — | 67.9% |
| Risk Flags | 1 flag | 1 flag |
Related comparisons
Data sourced from SEC EDGAR, Yahoo Finance, and official exchange filings. For informational purposes only. Not financial advice.